Esperion Therapeutics (ESPR) Tops Q2 EPS by $2.61, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020 4:05 PM EDT Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue
 Strong Capital Position with over $300 Million in Cash
 Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage
 Consistently High Month-Over-Month Growth for New Medicines With Acceleration in Second Half
 Conference Call and Webcast on August 10 at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results... More
